Document is current
Any future updates will be listed below
-
Authors
Thibaudin, Marion https://orcid.org/0000-0002-1046-5982
Roussot, Nicolas
Burlot, Chloé
Schmitt, Antonin
Vincent, Julie
Tharin, Zoé
Bengrine, Leila
Bellio, Hélène
Bertaut, Aurélie
Hampe, Léa
Daumoine, Susy
Rederstorff, Emilie
Peroz, Morgane
Huppe, Titouan
Derangère, Valentin
Rageot, David
Simard, John
Truntzer, Caroline
Fumet, Jean David
Ghiringhelli, Francois
-
Funding
Funding for this research was provided by:
Institut National Du Cancer (PHRC-K19-077)
- License Information
-
More Information
Article History
Received: 2 September 2024
Revised: 26 November 2024
Accepted: 25 December 2024
First Online: 17 January 2025
Competing interests
: F.G. has received honoraria for oral communications from Lilly, Sanofi, BMS, Astra Zeneca and Amgen, funding for clinical trials by Astra Zeneca, travel grants from Roche France, Amgen and Servier, and has served as an advisory board member for Merck Serano, Amgen, Roche France and Sanofi, all outside the scope of this submitted work. The trial was supported by grants from the French National Cancer Institute (PHRC-K19-077). XB2001 was provided by Xbiotech. All other authors declare no conflicts of interest.
